Mike Pearson’s New Prescription for the Pharmaceuticals Industry
Valeant Pharmaceuticals CEO Pearson’s $53 billion hostile bid to buy rival Allergan is the latest move by the former McKinsey consultant, who believes that capital is better spent on acquisitions than on R&D.
Michael Peltz
September 3, 2014